ANTCF (Aion Therapeutic) Days Payable: 439.89 (As of Jan. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aion Therapeutic Days Payable?

Aion Therapeutic ANTCF Days Payable is 439.89 as of Jan. 2025.

Aion Therapeutic's average Accounts Payable for the three months ended in Jan. 2025 was $1.80 Mil. Aion Therapeutic's Cost of Goods Sold for the three months ended in Jan. 2025 was $0.37 Mil. Hence, Aion Therapeutic's Days Payable for the three months ended in Jan. 2025 was 439.89.

The historical rank and industry rank for Aion Therapeutic's Days Payable or its related term are showing as below:

ANTCF's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 88.385
* Ranked among companies with meaningful Days Payable only.

Aion Therapeutic's Days Payable declined from Jan. 2024 (1,758.07) to Jan. 2025 (439.89). It may suggest that Aion Therapeutic accelerated paying its suppliers.

Aion Therapeutic Days Payable Historical Data

* Premium members only.

The historical data trend for Aion Therapeutic's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic Days Payable Chart

Aion Therapeutic Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Days Payable
Get a 7-Day Free Trial - - - - 1,251.86

Aion Therapeutic Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,758.07 551.46 478.17 582.50 439.89

ANTCF vs CBDY, GRPS, PLSH: Days Payable Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic Days Payable vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Days Payable distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Days Payable falls into.


Aion Therapeutic Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aion Therapeutic's Days Payable for the fiscal year that ended in Apr. 2024 is calculated as

Days Payable (A: Apr. 2024 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Apr. 2023 ) + Accounts Payable (A: Apr. 2024 )) / count ) / Cost of Goods Sold (A: Apr. 2024 )*Days in Period
=( (0 + 1.6581293445427) / 1 ) / 0.48345296122712*365
=1.6581293445427 / 0.48345296122712*365
=1,251.86

Aion Therapeutic's Days Payable for the quarter that ended in Jan. 2025 is calculated as:

Days Payable (Q: Jan. 2025 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Oct. 2024 ) + Accounts Payable (Q: Jan. 2025 )) / count ) / Cost of Goods Sold (Q: Jan. 2025 )*Days in Period
=( (1.775989813121 + 1.824668392888) / 2 ) / 0.37345590835471*365 / 4
=1.8003291030045 / 0.37345590835471*365 / 4
=439.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 439.89 mean?
Aion Therapeutic (ANTCF) has a Days Payable of 439.89 as of Jan. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aion Therapeutic and its competitors.
Is Aion Therapeutic's Days Payable too high?
Aion Therapeutic's current Days Payable is 439.89. The Drug Manufacturers industry median Days Payable is 88.39. Aion Therapeutic's value of 439.89 is 397.7% above this industry median.
How does Aion Therapeutic's Days Payable compare to CBDY and GRPS?
Aion Therapeutic's Days Payable of 439.89 can be compared against companies in the Drug Manufacturers industry. The industry median Days Payable is 88.39. Aion Therapeutic's value of 439.89 is 397.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.39, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aion Therapeutic's current Days Payable of 439.89 is 397.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aion Therapeutic and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aion Therapeutic's current Days Payable is 439.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aion Therapeutic stock overvalued right now?
Aion Therapeutic (ANTCF) has a current Days Payable of 439.89. The current Days Payable is 439.89 and 397.7% above the Drug Manufacturers industry median of 88.39. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aion Therapeutic (ANTCF), the current Days Payable is 439.89 as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aion Therapeutic Business Description

Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.